Biotech Values

[DewDiligence]

My interpretation of MNTA’s 6/29/09 PR and Wheeler’s comments from the R&R webcast is as follows: Each of the three M118 arms was numerically better than the heparin control arm on the composite* primary endpoint, but the trial was too small for non-inferiority relative to the control arm to be statsig for any individual M118 arm or the three M118 arms combined.

The interesting details to be presented at the TCT conference on Sep 24 are the data on how each M118 arm compared to the control arm on each of the seven components of the primary endpoint.

*The primary endpoint was a composite of these seven variables:

• Death during the 30 days post PCI procedure;
• Non-fatal MI during the 30 days post PCI procedure;
• Non-fatal stroke during the 30 days post PCI procedure;
• Repeat PCI during the 30 days post PCI procedure;
• Major bleeding during the 24 hours post PCI procedure;
• Thrombocytopenia during the 24 hours post PCI procedure; and
• Bailout use of a GP IIb/IIIa antiplatelet drug during the PCI procedure.